KO-2806 + cabozantinib

KO-2806 + cabozantinib is a combination therapy regimen under clinical investigation for advanced solid tumors, particularly clear cell renal cell carcinoma (ccRCC). **KO-2806** is a next-generation small molecule **farnesyl transferase inhibitor** (FTI) developed by Kura Oncology. FTIs block the post-translational modification (farnesylation) of proteins such as RAS, which are critical for cancer cell proliferation and survival. In preclinical models, KO-2806 has been shown to enhance the antitumor activity of cabozantinib in ccRCC and KRAS inhibitors in other cancers. **Cabozantinib** is a multi-targeted tyrosine kinase inhibitor that blocks several oncogenic and angiogenic kinases, including MET, RET, VEGFRs, AXL, and others, thereby inhibiting tumor growth, angiogenesis, and metastatic progression. The rationale for the combination is based on preclinical evidence for synergy, with the hope of overcoming resistance mechanisms and improving outcomes in cancers refractory to standard therapies[1][3][4][5][7].

Brand names

CometriqCabometyx